CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CDK
12 drives breast tumor initiation and trastuzumab resistance via
WNT
and
IRS
1‐ErbB‐
PI
3K signaling
Authors
Keywords
-
Journal
EMBO REPORTS
Volume -, Issue -, Pages -
Publisher
EMBO
Online
2019-08-30
DOI
10.15252/embr.201948058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Target Gene Screening: a web application for breast cancer target gene screening using multi-omics data analysis
- (2019) Hyung-Yong Kim et al. BRIEFINGS IN BIOINFORMATICS
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
- (2018) W Shi et al. ANNALS OF ONCOLOGY
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
- (2018) Srinivas R. Viswanathan et al. CELL
- A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases
- (2018) Yiqun Zhang et al. Cell Reports
- Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
- (2017) Hee-Joo Choi et al. JNCI-Journal of the National Cancer Institute
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
- (2017) Kalnisha Naidoo et al. MOLECULAR CANCER THERAPEUTICS
- CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
- (2017) Jerry F. Tien et al. NUCLEIC ACIDS RESEARCH
- Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
- (2017) Hee-Joo Choi et al. JNCI-Journal of the National Cancer Institute
- Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
- (2016) Andrew R. Green et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
- (2016) Tinghu Zhang et al. Nature Chemical Biology
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
- (2016) Anthony Ferrari et al. Nature Communications
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells
- (2015) KATJA STORCH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- MEL-18 loss mediates estrogen receptor–α downregulation and hormone independence
- (2015) Jeong-Yeon Lee et al. JOURNAL OF CLINICAL INVESTIGATION
- HER2-directed therapy: current treatment options for HER2-positive breast cancer
- (2015) Shahid Ahmed et al. Breast Cancer
- DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
- (2015) Min-Hyung Cho et al. Nature Communications
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
- (2014) Rachael Natrajan et al. JOURNAL OF PATHOLOGY
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Cancer stemness in Wnt-driven mammary tumorigenesis
- (2013) Joana Monteiro et al. CARCINOGENESIS
- Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice
- (2013) K Watanabe et al. ONCOGENE
- Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer
- (2012) A-Ram Choi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene
- (2012) Makoto Saito et al. FEBS LETTERS
- Expression of Wnt3 Activates Wnt/ -Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells
- (2012) Y. Wu et al. MOLECULAR CANCER RESEARCH
- The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
- (2012) Kristine Kleivi Sahlberg et al. Molecular Oncology
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Differential analysis of gene regulation at transcript resolution with RNA-seq
- (2012) Cole Trapnell et al. NATURE BIOTECHNOLOGY
- bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
- (2011) Pascal Jézéquel et al. BREAST CANCER RESEARCH AND TREATMENT
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
- (2011) D. Blazek et al. GENES & DEVELOPMENT
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Genome profiling of ERBB2-amplified breast cancers
- (2010) Fabrice Sircoulomb et al. BMC CANCER
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
- (2010) B. Bartkowiak et al. GENES & DEVELOPMENT
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
- (2010) Cole Trapnell et al. NATURE BIOTECHNOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
- (2008) Madhuri Kakarala et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now